DNA Methylation and Hydroxymethylation Levels in Patients With Coronary Heart Disease

Chongqing Medical University1 site in 1 country200 target enrollmentJanuary 1, 2018

ConditionsCoronary Heart Disease

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Coronary Heart Disease
Sponsor: Chongqing Medical University
Enrollment: 200
Locations: 1
Primary Endpoint: DNA Methylation and Hydroxymethylation Levels
Status: Completed
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this trial is to investigate the relationship between DNA methylation and hydroxymethylation and the expression of DNMTs, TET family gene and the degree of coronary heart disease.

Detailed Description

1. To determine the levels of DNA methylation and hydroxymethylation with coronary heart disease. 2. To investigate the relationship between DNA methylation and hydroxymethylation and the degree of coronary atherosclerosis.

Registry

clinicaltrials.gov

Start Date

January 1, 2018

End Date

October 1, 2018

Last Updated

6 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Chongqing Medical University

Responsible Party

Principal Investigator

Dongying Zhang

doctor

Chongqing Medical University

Eligibility Criteria

Inclusion Criteria

•Male and Female. Patients older than 65 years old who are willing to participate in the study. CHD patients was defined as at least one lesion in a coronary artery or branches in coronary angiograms. Control group was defined as people with negative findings in coronary angiograms.

Exclusion Criteria

•Patients with concurrent infection or any documented inflammatory illness, such as arthritis or connective tissue diseases, or any other malignancy. Patients with a history of cardiomyopathy. Pregnant women. Severe hepatic dysfunction or End-stage renal failure. Uncontrolled hypertension.